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LOW DOSE ANTI-THYMOCYTE GLOBULIN FOR GRAFT-VERSUS-HOST
DISEASE PROPHYLAXIS OF MISMATCHED UNRELATED PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH
ACUTE MYELOGENOUS LEUKEMIA
Kim, H.-J., Min, W.-S., Eom, K.-S., Cho, B.-S., Min, C.-K., Lee, S.,
Cho, S.-G., Lee, J.-W., Kim, C.-C. Catholic HSCT Center, St. Mary’s
Hospital Catholic University of Korea College of Medicine, Seoul, Republic
of Korea.
Anti-thymocyte globulin (ATG) has been introduced in prevent-
ing acute graft-versus-host disease (AGvHD) in several studies.
Many of them suggest that ATG at a total dose range of 4.515
mg/kg reduces the risk of severe AGvHD but increases the risk of
infections. We tried to investigate the role of ATG in HLA-mis-
matched unrelated hematopoietic stem cell transplantations
(uHSCT), specifically in patients who received G-CSF mobilized
peripheral blood stem cells (PBSCs) or from allele(s)/antigen mis-
matched unrelated donors from worldwide donor registries. Sixty
five patients with intermediate to unfavourable risk AML who re-
ceived HLA-mismatched uHSCT from the available Asian as well
as Caucasian donors were enrolled. We compared 2 different
groups according to the use of ATG (group 1) or not (group 2).
The addition of ATG (thymoglobulin, Genzyme), at a dose of
1.25 mg per kilogram of body weight per day for 2 consecutive
days, for recipients who received either PBSCs and/or from mis-
matched unrelated donors (group 1, N5 35); this was added to pre-
vent the development of AGvHD together with our standard
regimen which consisted of methotrexate (10 mg/m2 intravenously
bolus on day11; andmethotrexate 5mg/m2 intravenously bolus, on
days 13, 16, 111) and tacrolimus starting at day –1. G-CSF was
administered in all patients at a dose of 5 mg/kg subcutaneously
per day from D1 7 after transplantation until neutrophil recovery.
The median age was 38 (range, 16–65) and the median follow-up
duration was 24 months (range, 3–72). The majority of patients
had intermediate or unfavourable cytogenetic features. The main
conditioning regimen consisted in cyclophosphamide plus total
body irradiation. The transplanted patients were all successfully en-
grafted. The median time to neutrophil (.0.5  109/kg) and plate-
let (.20  109/kg) recovery was 15 vs 17 days, 14 vs 17 days in the
group 1 and 2, respectively. The overall incidence of AGvHD and
chronic GvHD was 38% and 41%; 33% and 35%, 37% and 48%
for patients with group 1 and group2, respectively. Nine (14%) pa-
tients were relapsed so far. The comparison of estimated probability
of disease-free survival rate at 2-year for each group was 89% vs
74%, respectively. The estimated probability of event-free survival
rate at 2-year was 65% vs 51%, respectively. The overall 2-year
non-relapse TRMwas 14%. These results suggest that the uHSCT
performed with a very low dose of ATG (total 2.5 mg/kg) are feasi-
ble with a promising outcome.378
TACROLIMUS, SIROLIMUS AND ANTITHYMOCYTE GLOBULIN (rATG)
FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS FOR UNRELATED DO-
NOR HEMATOPOIETIC CELL TRANSPLANTATION
Aljitawi, O.S., Nakamura, R., Palmer, J., Senitzer, D., Pullarkat, V.,
Briggs, A., Cai, J.-L., Rosenthal, J., Schriber, J., Snyder, D.,
Nademanee, A., Parker, P., Forman, S. City of Hope Comprehensive
Cancer Center, Duarte, CA.
The effect of adding ATG to Tacrolimus/Sirolimus combination
in graft-versus-host disease (GVHD) prophylaxis is largely un-
known.We reviewed our records for patients who underwent unre-
lated transplants and received this combination for GVHD
prophylaxis. Nineteen patients were identified who received their
transplants between 8/06 and 02/07. Median age at time of trans-plant was 51.1 years (17–61.5). Nine recipients were males and 10
were females. The indications for transplant were as follows: ALL
n 5 9, AML n 5 5, NHL n 5 2, MDS n 5 2 and CML n 5 1.
Twelve patients were in remission (CR1 5 10, $CR2: n 5 2),
and seven had refractory disease. Eight patients received reduced-
intensity conditioning (fludarbine/melphalan: n 5 8) and 11 re-
ceived full-intensity conditioning (FTBI/VP-16: n 5 8, FTBI/Cy-
toxan: n5 3). All received peripheral blood hematopoietic stem cell
products except for two patients who received bone marrow prod-
ucts with the median CD341cell dose of 6.82 (1.56–9.46) x106/
Kg. Donors were molecularly matched in A, B, C, and DR in 11 pa-
tients; the remaining donors were mismatch in class I (n 5 5) or
both class I and II (n 5 3). After a median follow-up of 9 months
16 patients are alive. Two deaths were related to infections within
the first hundred days and not associated with acute GVHD. One
patient died of relapsed AML. The probabilities of one-year overall
survival, disease-free survival, relapse, and non-relapse mortality
were 78%, 80%, 11%, and 11%, respectively. Ten patients devel-
oped acute GVHD with median onset of 24 days (7–35 days) after
transplantation including five (26%) grade II and two (11%) grade
III. We observed no grade IV GVHD in this cohort. Two patients
developed chronic GVHD (limited: n 5 1, extensive: n 5 1). Pa-
tients tolerated rATG treatment well except for one who developed
atrial fibrillation. Three patients developed thrombotic microangi-
opathy that required discontinuation of tacrolimus and sirolimus.
Six of 15 CMV seropositive recipients developed reactivation of
CMV including one with CMV pneumonia. None had reactivation
of EBV. Eight patients had at least one documented bacterial infec-
tion.
Conclusion: In conclusion, the combination of Tacrolimus/siro-
limus/rATG appears to be well tolerated, with a low rate of acute
GVHD in this high risk group of patients without increased risk
of early relapse or CMV/EBV reactivation. A prospective trial of
this new combination in unrelated donor transplants is underway
at our institution.379
INTRA-ARTERIAL CATHETER DIRECTED IMMUNOSUPPRESSIVE THER-
APY FOR STEROID RESISTANT OR DEPENDENT GRAFT VS. HOST DIS-
EASE (GVHD)
Shapira, M.Y.1, Bloom, A.I.2, Or, R.1, Resnick, I.B.1, Aker, M.1,
Bitan,M.1, Slavin, S.1, Verstandig, A.2. 1Hadassah – HebrewUniversity
Medical Center, Jerusalem, Israel; 2Hadassah – HebrewUniversityMed-
ical Center, Jerusalem, Israel.
Introduction: Prolonged treatment of graft vs. host disease
(GVHD) is extremely immunosuppressive. Local therapy with in-
tra-arterial (IA) injection of steroids may induce remission with
lower extent of systemic immune suppression. Here, we present
our experience with IA treatment of gastrointestinal (GI) and/or he-
patic steroid resistant/dependent GVHDwith 2 consecutive proto-
cols.Methods:Thirty five patients (37 GVHD events (hepatic, n5
15), (GI, n 5 16), (combined, n 5 6)) were treated with 53 IA ses-
sions. Results: We found that IA steroid therapy was associated
with partial and complete remission among patients with steroid re-
sistant/dependent hepatic or GI GVHD. Hepatic partial response
was observed in 14 (66.6%) patients among whom 7 (33.3%)
reached complete response. GI partial response was observed in
19 (86.4%) patients among whom 12 (54.4%) reached complete re-
sponse.Most side effects were minor. An early administration of the
local therapy, female gender, myeloid basic disease, and a non-ac-
tive status of the basic disease at the day of transplantation were
found related for predicting a better response for the intra-arterial
treatment. The use of high dose steroids in the hepatic IA protocol
from was at least as good as intermediate dose steroids with meth-
otrexate and may be safer. Conclusion: Intra-arterial catheter
guided steroid therapy is safe and effective in steroid resistant/de-
pendent GVHD. Hepatic artery treatment with methotrexate can
be safely substituted with high dose IAmethylprednisolone. Further
research is warranted characterizing the patients benefit most.
